Covance Collaborating with Sleep Study Experts
Covance (Princeton, NJ) is increasing its capacity to support specialized sleep studies through a new collaboration with Sleep Medicine Associates. The collaboration gives Covance access to Sleep Medicine Associates’ eight-bed, state-of-the art research facility in Evansville, IN, along with specialized support for studies in restless leg syndrome, insomnia, narcolepsy, fibromyalgia, and other conditions related to the central nervous system.
Covance reports that Board certified sleep expert David Cocanower, MD, of Sleep Medicine Associates, will provide specialized sleep and neurological monitoring and will consult on sleep-specific protocols and study design.
“We are excited to expand our sleep therapeutic expertise, capacity, and recruitment capabilities to better support client needs in this highly specialized area,” said Randall Stoltz, M.D., CPI, medical director, Covance. “Sleep Medicine Associates adds industry-leading expertise and cutting edge technology to Covance’s portfolio.”
Sleep Medicine Associates is fully accredited by the American Academy of Sleep Medicine.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
